ORCID Profile
0000-0001-6015-7841
Current Organisation
The University of Edinburgh
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Association for Cancer Research (AACR)
Date: 28-06-2021
DOI: 10.1158/2159-8290.CD-20-1647
Abstract: The AURORA program, through the genomic and transcriptomic analyses of matched primary and metastatic s les from 381 patients with breast cancer, coupled with prospectively collected clinical data, identified genomic alterations enriched in metastases and prognostic biomarkers. ESCAT tier I/II alterations were detected in more than half of the patients. This article is highlighted in the In This Issue feature, p. 2659
Publisher: BMJ
Date: 08-2023
DOI: 10.1136/BMJOPEN-2023-075187
Abstract: The top research priority for cavernoma, identified by a James Lind Alliance Priority setting partnership was ‘Does treatment (with neurosurgery or stereotactic radiosurgery) or no treatment improve outcome for people diagnosed with a cavernoma?’ This pilot randomised controlled trial (RCT) aims to determine the feasibility of answering this question in a main phase RCT. We will perform a pilot phase, parallel group, pragmatic RCT involving approximately 60 children or adults with mental capacity, resident in the UK or Ireland, with an unresected symptomatic brain cavernoma. Participants will be randomised by web-based randomisation 1:1 to treatment with medical management and with surgery (neurosurgery or stereotactic radiosurgery) versus medical management alone, stratified by prerandomisation preference for type of surgery. In addition to 13 feasibility outcomes, the primary clinical outcome is symptomatic intracranial haemorrhage or new persistent rogressive focal neurological deficit measured at 6 monthly intervals. An integrated QuinteT Recruitment Intervention (QRI) evaluates screening logs, audio recordings of recruitment discussions, and interviews with recruiters and patients arents/carers to identify and address barriers to participation. A Patient Advisory Group has codesigned the study and will oversee its progress. This study was approved by the Yorkshire and The Humber—Leeds East Research Ethics Committee (21/YH/0046). We will submit manuscripts to peer-reviewed journals, describing the findings of the QRI and the Cavernomas: A Randomised Evaluation (CARE) pilot trial. We will present at national specialty meetings. We will disseminate a plain English summary of the findings of the CARE pilot trial to participants and public audiences with input from, and acknowledgement of, the Patient Advisory Group. ISRCTN41647111 .
Publisher: Elsevier BV
Date: 10-2021
Publisher: European Respiratory Society (ERS)
Date: 15-06-2023
DOI: 10.1183/23120541.00167-2023
Abstract: Chronic breathlessness, a persistent and disabling symptom despite optimal treatment of underlying causes, is a frightening symptom with serious and widespread impact on patients and their carers. Clinical guidelines support the use of morphine for the relief of chronic breathlessness in common long-term conditions, but questions remain around clinical effectiveness, safety and longer term ( days) administration. This trial will evaluate the effectiveness of low-dose oral modified-release morphine in chronic breathlessness. This is a multicentre, parallel group, double-blind, randomised, placebo-controlled trial. Participants (n=158) will be opioid-naïve with chronic breathlessness due to heart or lung disease, cancer or post-coronavirus disease 2019. Participants will be randomised 1:1 to 5 mg oral modified-release morphine lacebo twice daily and docusate lacebo 100 mg twice daily for 56 days. Non-responders at Day 7 will dose escalate to 10 mg morphine lacebo twice daily at Day 15. The primary end-point (Day 28) measure will be worst breathlessness severity (previous 24 h). Secondary outcome measures include worst cough, distress, pain, functional status, physical activity, quality of life, and early identification and management of morphine-related side-effects. At Day 56, participants may opt to take open-label, oral modified-release morphine as part of usual care and complete quarterly breathlessness and toxicity questionnaires. The study is powered to be able to reject the null hypothesis and an embedded normalisation process theory-informed qualitative substudy will explore the adoption of morphine as a first-line pharmacological treatment for chronic breathlessness in clinical practice if effective.
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540795
Abstract: File with the supplementary material & methods, supplementary tables and supplementary figure.
Publisher: JMIR Publications Inc.
Date: 20-09-2021
DOI: 10.2196/31976
Abstract: Cancer survivors frequently report a range of unmet psychological and supportive care needs these often continue after treatment has finished and are predictive of psychological distress and poor health-related quality of life. Web-based interventions demonstrate good efficacy in addressing these concerns and are more accessible than face-to-face interventions. Finding My Way (FMW) is a web-based, psycho-educational, and cognitive behavioral therapy intervention for cancer survivors developed in Australia. Previous trials have demonstrated that FMW is acceptable, highly adhered to, and effective in reducing the impact of distress on quality of life while leading to cost savings through health resource use reduction. This study aims to adapt the Australian FMW website for a UK cancer care context and then undertake a single-blinded, randomized controlled trial of FMW UK against a treatment-as-usual waitlist control. To an extent, our trial design replicates the existing Australian randomized controlled trial of FMW. Following a comprehensive adaptation of the web resource, we will recruit 294 participants (147 per study arm) from across clinical sites in North West England and North Wales. Participants will have been diagnosed with cancer of any type in the last 6 months, have received anticancer treatment with curative intent, be aged ≥16 years, be proficient in English, and have access to the internet and an active email address. Participants will be identified and recruited through the National Institute for Health Research clinical research network. Measures of distress, quality of life, and health economic outcomes will be collected using a self-report web-based questionnaire at baseline, midtreatment, posttreatment, and both 3- and 6-month follow-up. Quantitative data will be analyzed using intention-to-treat mixed model repeated measures analysis. Embedded semistructured qualitative interviews will probe engagement with, and experiences of using, FMW UK and suggestions for future improvements. The website adaptation work was completed in January 2021. A panel of cancer survivors and health care professionals provided feedback on the test version of FMW UK. Feedback was positive overall, although minor updates were made to website navigation, inclusivity, terminology, and the wording of the Improving Communication and Sexuality and Intimacy content. Recruitment for the clinical trial commenced in April 2021. We aim to report on findings from mid-2023. Replication studies are an important aspect of the scientific process, particularly in psychological and clinical trial literature, especially in different geographical settings. Before replicating the FMW trial in the UK setting, content updating was required. If FMW UK now replicates Australian findings, we will have identified a novel and cost-effective method of psychosocial care delivery for cancer survivors in the United Kingdom. International Standard Randomized Controlled Trial Number (ISRCTN) 14317248 www.isrctn.com/ISRCTN14317248 DERR1-10.2196/31976
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540798
Abstract: Supplementary file with the listing of the liver genes excluded from transcriptomic analyses.
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540798.V1
Abstract: Supplementary file with the listing of the liver genes excluded from transcriptomic analyses.
Publisher: Elsevier BV
Date: 05-2022
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.C.6549478.V1
Abstract: Abstract AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequencing, 152 RNA sequencing, 67 single nucleotide polymorphism arrays), we found a driver role for i GATA1 /i and i MEN1 /i somatic mutations. Metastases were enriched in i ESR1, PTEN, CDH1, PIK3CA /i , and i RB1 /i mutations i MDM4 /i and i MYC /i lifications and i ARID1A /i deletions. An increase in clonality was observed in driver genes such as i ERBB2 /i and i RB1 /i . Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-enriched switching was associated with i TP53 /i and/or i PIK3CA /i mutations. Metastases had lower immune score and increased immune-permissive cells. High tumor mutational burden correlated to shorter time to relapse in HR sup + /sup /HER2 sup − /sup cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could affect treatment strategies in MBC. Significance: The AURORA program, through the genomic and transcriptomic analyses of matched primary and metastatic s les from 381 patients with breast cancer, coupled with prospectively collected clinical data, identified genomic alterations enriched in metastases and prognostic biomarkers. ESCAT tier I/II alterations were detected in more than half of the patients. i a href="ancerdiscovery/article/doi/10.1158/2159-8290.CD-11-11-ITI" target="_blank" This article is highlighted in the In This Issue feature, p. 2659 /a /i /
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540795.V1
Abstract: File with the supplementary material & methods, supplementary tables and supplementary figure.
Publisher: JMIR Publications Inc.
Date: 12-07-2021
Abstract: ancer survivors frequently report a range of unmet psychological and supportive care needs these often continue after treatment has finished and are predictive of psychological distress and poor health-related quality of life. Web-based interventions demonstrate good efficacy in addressing these concerns and are more accessible than face-to-face interventions. i Finding My Way /i (FMW) is a web-based, psycho-educational, and cognitive behavioral therapy intervention for cancer survivors developed in Australia. Previous trials have demonstrated that i FMW /i is acceptable, highly adhered to, and effective in reducing the impact of distress on quality of life while leading to cost savings through health resource use reduction. his study aims to adapt the Australian i FMW /i website for a UK cancer care context and then undertake a single-blinded, randomized controlled trial of i FMW UK /i against a treatment-as-usual waitlist control. o an extent, our trial design replicates the existing Australian randomized controlled trial of i FMW. /i Following a comprehensive adaptation of the web resource, we will recruit 294 participants (147 per study arm) from across clinical sites in North West England and North Wales. Participants will have been diagnosed with cancer of any type in the last 6 months, have received anticancer treatment with curative intent, be aged ≥16 years, be proficient in English, and have access to the internet and an active email address. Participants will be identified and recruited through the National Institute for Health Research clinical research network. Measures of distress, quality of life, and health economic outcomes will be collected using a self-report web-based questionnaire at baseline, midtreatment, posttreatment, and both 3- and 6-month follow-up. Quantitative data will be analyzed using intention-to-treat mixed model repeated measures analysis. Embedded semistructured qualitative interviews will probe engagement with, and experiences of using, i FMW UK /i and suggestions for future improvements i . /i he website adaptation work was completed in January 2021. A panel of cancer survivors and health care professionals provided feedback on the test version of i FMW UK. /i Feedback was positive overall, although minor updates were made to website navigation, inclusivity, terminology, and the wording of the i Improving Communication /i and i Sexuality and Intimacy /i content. Recruitment for the clinical trial commenced in April 2021. We aim to report on findings from mid-2023. eplication studies are an important aspect of the scientific process, particularly in psychological and clinical trial literature, especially in different geographical settings. Before replicating the i FMW /i trial in the UK setting, content updating was required. If i FMW UK /i now replicates Australian findings, we will have identified a novel and cost-effective method of psychosocial care delivery for cancer survivors in the United Kingdom. nternational Standard Randomized Controlled Trial Number (ISRCTN) 14317248 www.isrctn.com/ISRCTN14317248 ERR1-10.2196/31976
Publisher: Elsevier BV
Date: 02-2019
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Peter Hall.